Synthesis and experimental study of norfloxacin labeled with technecium-99m as a potential agent for infection imaging

Iranian Journal of Nuclear Medicine

Volumn 23, Issue 2, 2015, Pages 73-81

  Sazonova, Svetlana Ivanovna ^a,b   Lishmanov, Yuriy Borisovich ^a   Varlamova, Natalia Valerievna ^b   Skuridin, Viktor Sergeevich ^b   Ilushenkova, Yulia Nikolayevna ^a   Karpova, Maria Rostislavovna ^c   Nesterov, Yevgeniy Alexandrovich ^b  

^a CARDIOLOGY RESEARCH INSTITUTE   (Russian Federation)

^b NATIONAL RESEARCH TOMSK POLYTECHNIC UNIVERSITY   (Russian Federation)

^c SIBERIAN STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Infection; Inflammation; Norfloxacin; Scintigraphy; Technecium 99m

Indexed keywords

NORFLOXACIN; NORFLOXACIN TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; COLLOID; CONTROLLED STUDY; DISK DIFFUSION; DRUG DISTRIBUTION; DRUG PURITY; DRUG STABILITY; DRUG SYNTHESIS; EXPERIMENTAL STUDY; FEASIBILITY STUDY; IN VITRO STUDY; ISOTOPE LABELING; KIDNEY; LIVER; MALE; MYOSITIS; NONHUMAN; PLASMA CLEARANCE; RADIOCHEMISTRY; RAT; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THIN LAYER CHROMATOGRAPHY;

EID: 84938094736     PISSN: 16812824     EISSN: 20082509     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Petruzzi N, Shanthly N, Thakur M. Recent trends in soft-tissue infection imaging. Semin Nucl Med. 2009 Mar;39(2):115-23
2. Britton KE, Vinjamuri S, Hall AV, Solanki K, Siraj QH, Bomanji J, Das S. Clinical evaluation of technetium-99m infecton for the localisation of bacterial infection. Eur J Nucl Med. 1997 May;24(5):553-6
3. Dumarey N, Blocklet D, Appelboom T, Tant L, Schoutens A. Infecton is not specific for bacterial osteoarticular infective pathology. Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):530-5
4. Pucar D, Janković Z, Dugonjić S, Popović Z. Estimation of 99mTc-ciprofloxacin accumulation indexes in bone and joint bacterial infections. Vojnosanit Pregl. 2009 May;66(5):395-8
5. Sarda L, Saleh-Mghir A, Peker C, Meulemans A, Crémieux AC, Le Guludec D. Evaluation of (99m)Tcciprofloxacin scintigraphy in a rabbit model of Staphylococcus aureus prosthetic joint infection. J Nucl Med. 2002 Feb;43(2):239-45
6. Sonmezoglu K, Sonmezoglu M, Halac M, Akgün I, Türkmen C, Onsel C, Kanmaz B, Solanki K, Britton KE, Uslu I. Usefulness of 99mTc-ciprofloxacin (infecton) scan in diagnosis of chronic orthopedic infections: comparative study with 99mTc-HMPAO leukocyte scintigraphy. J Nucl Med. 2001 Apr;42(4):567-74
7. Skuridin VS, Varlamova NV, Belyanin ML, Sazonova SI, Konkovskaya YN, Takhauov RM: Synthesis and biological characterization of 99mTc-labeled ciprofloxacin. Pharm Chem J. 2009; 43(9): 516-20
8. Ibrahim IT, Motaleb MA, Attalah KM. Synthesis and biological distribution of 99mTc-norfloxacin complex, a novel agent for detecting sites of infection. J Radioanal Nucl Chem. 2010;285:431-36
9. Zhang S, Zhang W, Wang Y, Jin Z, Wang X, Zhang J, Zhang Y. Synthesis and biodistribution of a novel (99m)TcN complex of norfloxacin dithiocarbamate as a potential agent for bacterial infection imaging. Bioconjug Chem. 2011 Mar 16;22(3):369-75
10. Nayak DK, Baishya R, Halder KK, Sen T, Sarkar BR, Ganguly S, Das MK, Debnath MC. Evaluation of (99m)Tc(i)-tricarbonyl complexes of fluoroquinolones for targeting bacterial infection. Metallomics. 2012 Nov;4(11):1197-208
11. Erfani M, Doroudi A, Hadisi L, Andishmand A, Mirshojaei SF, Shafiei M. (99m) Tc-tricabonyl labeling of ofloxacin and its biological evaluation in Staphylococcus aureus as an infection imaging agent. J Labelled Comp Radiopharm. 2013 Oct;56(12):627-31
12. Varlamova NV, Skuridin VS, Sazonova SI. Preparation and medical and biological testing of 99mTcnorfloxacin. Bull Siberian Med. 2010; 9(6):108-15
13. Mokrushina GA, Kotovskaya SK, Baskakova ZM, Petrova GM, Kolmakova TV, Charushin VN, Rusinov VL, Chupakhin ON. Improved method for the synthesis of norfloxacin. Pharm Chem J. 1996;30(8): 540-42
14. Titov IV, Dorofeev VL, Arzamastsev AP. The Use of UV-Spectrometry method to authenticate fluoroquinolone drugs. Vestn VGU (Ser: Khim Biol Farm) 2004;2:264-69
15. Rahman A, Hossain MA, Paul SK, Sultana S, Haque N, Kabir MR, Hoque SM. Methicillin-resistant coagulasenegative staphylococci (MRCoNS) by disk diffusion method. Mymensingh Med J. 2013 Apr;22(2):229-31
16. Yakovlev VP. Fluoroquinolone. Consilium Medicum. 2006; 8(1):35-41
17. Sierra JM, Rodriguez-Puig D, Soriano A, Mensa J, Piera C, Vila J. Accumulation of 99mTc-ciprofloxacin in Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2008 Jul;52(7):2691-2
18. Alexander K, Drost WT, Mattoon JS, Kowalski JJ, Funk JA, Crabtree AC. Binding of ciprofloxacin labelled with technetium Tc 99m versus 99mTc-pertechnetate to a live and killed equine isolate of Escherichia coil. Can J Vet Res. 2005 Oct;69(4):272-7